Recent Updates
Recently added Catalysts
GERN

JANUARY 2016

Monday, January 11, 2016 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: JANUARY 2016 CORPORATE PRESENTATION HANDOUT

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
4.4%
average across 4 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
Imetelstat
Phase 3 · Myelofibrosis

Full Press Release Details

JANUARY 2016 CORPORATE PRESENTATION HANDOUT
ShareAdd on Google
Tags: GERN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 11, 2016

Biotech snapshot

Cash runway
$349M liquidity · $5M/mo burn
~66 mo
Minimal dilution risk
Lead asset
ImetelstatPhase 3
Myelofibrosis →

Catalyst track record

+48%
best trade around GERN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GERN.

See every catalyst's timing & PoA →